NCT03399539 2024-11-04Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple MyelomaMayo ClinicPhase 1 Completed8 enrolled
NCT01794520 2023-04-10Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple MyelomaAbbViePhase 1/2 Completed117 enrolled 29 charts
NCT03312530 2023-02-28A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple MyelomaHoffmann-La RochePhase 1/2 Completed49 enrolled 24 charts
NCT01794507 2021-08-02A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard TherapyAbbViePhase 1 Completed66 enrolled
NCT02265731 2021-08-02Study Evaluating Venetoclax in Subjects With Hematological MalignanciesAbbViePhase 1/2 Completed38 enrolled
NCT02391480 2019-11-29A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With CancerAbbViePhase 1 Completed128 enrolled